Pharmacy Considerations for Hyperglycemia Risk and Early Intervention in HR+/HER2-Negative Advanced Breast Cancer

In this segment, Dr. Neil Iyengar moderates a pharmacy-focused discussion with Heather Moore, CPP, PharmD on identifying and managing factors that contribute to hyperglycemia risk in patients with HR+/HER2-negative advanced breast cancer receiving PI3K or AKT pathway inhibitors. Ms. Moore highlights key patient-specific considerations, including preexisting metabolic conditions, concomitant medications, and lifestyle factors that may exacerbate glucose elevations. She discusses the pharmacist’s role in reviewing medication profiles for potential interactions, reinforcing dietary and physical activity guidance, and setting expectations around glucose monitoring. The conversation also addresses how pharmacists counsel patients on recognizing early signs of hyperglycemia and coordinating timely intervention, including collaboration with the broader care team when additional support is needed. This segment illustrates how proactive pharmacy involvement supports early risk mitigation, enhances patient education, and contributes to safer metabolic management during targeted therapy.